Maze Therapeutics Inc
MAZE
View Detailed Chart
30.380USD
-1.330-4.19%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.33BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.19%
5 Days
-36.75%
1 Month
-33.36%
6 Months
+12.52%
Year to Date
-26.67%
1 Year
+169.57%
View Detailed Chart
TradingKey Stock Score of Maze Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Maze Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 37 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Maze Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Maze Therapeutics Inc Highlights
StrengthsRisks
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -9.96, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 40.80M shares, increasing 2.26% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 114.66K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
65.500
Target Price
+33.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Maze Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Maze Therapeutics Inc Info
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Ticker SymbolMAZE
CompanyMaze Therapeutics Inc
CEOColoma (Jason V)
Websitehttps://www.mazetx.com/
Related Instruments
-2.09%
-1.92%
+0.51%
+2.74%
+0.59%
-0.81%
-1.02%
-1.24%
-0.39%
-1.92%
-0.99%
+0.34%
-0.19%
-1.50%
-4.56%
0.00%
-0.54%
-2.51%
-2.81%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66904.870
+914.110 (+1.39%)
275.340
+1.990 (+0.73%)
2021.230
+37.690 (+1.90%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
